Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in of performing real-time drug screening on tissue taken during surgery in patients with relapsed ultra rare brain tumors (BCOR -altered, MN1-altered, CNS Sarcomas, other rare brain tumors) and of having a specialized tumor board assign a treatment plan based on the results of the drug screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed ultra rare brain tumors to receive the most ef

Trial Details

NCT ID
NCT07851636
Phase
NA
Sponsor
Adriana Fonseca
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Personalized Treatment Recommendation
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Patients must have a relapse or recurrence of one of the following rare brain tumors:
  • CNS sarcoma (e.g. EWS, CIC, DICER1 altered)
  • BCOR altered tumors (e.g. BCOR ITD; BCOR, BCORL1, EP300, fused)
  • Mesenchymal tumors (e.g. FET::CREB altered tumors)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →